Blog

  • Moon phase today explained: What the moon will look like on November 30, 2025

    Moon phase today explained: What the moon will look like on November 30, 2025

    We’re just a few days away from the Full Moon now, so the moon is nice and bright tonight. There’s plenty for you to see when you look up, so keep reading to find out exactly what you…

    Continue Reading

  • Russia’s Baikonur Cosmodrome Damaged After Latest Soyuz Launch

    Russia’s Baikonur Cosmodrome Damaged After Latest Soyuz Launch

    Russia’s main launch facility for sending cosmonauts into space was damaged during the latest launch of a Soyuz capsule, prompting emergency repairs.

    The accident at the Baikonur cosmodrome will result in a suspension of all manned launches from…

    Continue Reading

  • Assessing Cmb.Tech After Strategic Green Energy Partnerships and a 10% Price Surge

    Assessing Cmb.Tech After Strategic Green Energy Partnerships and a 10% Price Surge

    • Ever wondered if Cmb.Tech is genuinely a bargain or just another stock passing through the market spotlight? You are not alone. A lot of investors are watching for hints about its true value.

    • Cmb.Tech’s price has jumped 10.3% in the last week and is now up 15.2% over the past month, but it is still down 11.9% over the past year, showing both upside potential and a history of volatility.

    • Much of the recent momentum follows updates about Cmb.Tech’s strategic partnerships in green energy solutions, which have drawn positive attention from environmentally focused investors. Industry news around new regulations and funding for sustainable technologies has also helped shine a light on the company’s growth prospects.

    • On our valuation checklist, Cmb.Tech scores a 3 out of 6, putting it in the middle of the pack for undervaluation signals. Let’s break down what goes into this score and explore the traditional methods. Keep an eye out for a smarter, more comprehensive approach coming up at the end of this article.

    Find out why Cmb.Tech’s -11.9% return over the last year is lagging behind its peers.

    A Discounted Cash Flow (DCF) model estimates the intrinsic value of a business by projecting its future cash flows and discounting them back to today’s dollars. This approach helps investors see the true worth of a company, beyond current market sentiment, by focusing on what it can actually generate in free cash.

    Looking at Cmb.Tech, the latest reported Free Cash Flow (FCF) stands at approximately $-502 million. While this is a negative figure now, forecasts show a sharp turnaround. Analysts project FCF to swing to $634 million by the end of 2027, with further projections (using Simply Wall St’s growth methodology) rising to over $4.2 billion by 2035. These figures indicate expectations of accelerating growth over the next decade.

    All cash flows were calculated in US dollars. By discounting these future values to the present, the DCF model estimates Cmb.Tech’s intrinsic value at $138.49 per share. This price is a striking 93.1% higher than where the stock is currently trading, suggesting substantial undervaluation.

    Result: UNDERVALUED

    Our Discounted Cash Flow (DCF) analysis suggests Cmb.Tech is undervalued by 93.1%. Track this in your watchlist or portfolio, or discover 914 more undervalued stocks based on cash flows.

    CMBT Discounted Cash Flow as at Nov 2025

    Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Cmb.Tech.

    The Price-to-Earnings (PE) ratio is a popular and intuitive metric for valuing profitable companies, as it shows how much investors are willing to pay for each unit of earnings. For businesses like Cmb.Tech, which have moved into profitability and are expected to grow, the PE ratio helps contextualize current and future earning power.

    Continue Reading

  • How Fresh Analyst Sentiment Is Shaping the Tesco Story

    How Fresh Analyst Sentiment Is Shaping the Tesco Story

    Analysts have recently revised their price targets for Tesco, citing a marginal decrease in the discount rate from 7.99% to 7.95%. This shift reflects growing confidence in Tesco’s stability and a slight reduction in perceived risk. Stay tuned to find out how you can keep up with key updates as analyst sentiment continues to shape the Tesco stock narrative.

    Analyst Price Targets don’t always capture the full story. Head over to our Company Report to find new ways to value Tesco.

    Recent analyst commentary on Tesco has provided insight into market perspectives ahead of the company’s key earnings dates and amidst notable shifts in target price forecasts. The following presents a balanced view of both bullish and bearish observations reported by covering firms.

    🐂 Bullish Takeaways

    • JPMorgan raised its price target on Tesco from 400 GBp to 450 GBp and maintained an Overweight rating, reflecting increased confidence in the company’s earnings outlook.

    • JPMorgan placed Tesco shares on “Positive Catalyst Watch” ahead of upcoming earnings, signaling firm expectations of positive developments or upside surprises in disclosed results.

    • The firm’s revised forecasts are now comfortably above guidance, after raising first half estimates by 17%, fiscal year 2026 by 7%, and fiscal year 2027 onwards by an average of 4%.

    • Analysts reward Tesco’s ability to deliver stronger earnings projections against prior expectations, demonstrating solid execution and effective management.

    🐻 Bearish Takeaways

    • Despite the optimistic target revisions, JPMorgan’s commentary implies heightened expectations may be increasingly priced in. This may reduce near-term upside if future results fall short.

    • Ongoing focus on guidance versus actual performance may reintroduce volatility if Tesco fails to deliver on higher analyst projections.

    Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

    LSE:TSCO Community Fair Values as at Nov 2025
    • Pacvue has partnered with Tesco Media to enhance retail media activation. This collaboration gives brands access to new tools for optimizing and measuring sponsored product campaigns on Tesco platforms. The partnership includes the addition of “Sales at Checkout” reporting metrics and automation options.

    • Solution International’s ‘Grow with Peppa’ merchandise line, featuring the popular character, has broadened its presence in Tesco stores and through Tesco’s online outlets across the UK and Ireland. The campaign is expected to drive significant engagement in the baby feeding category and generate more than SEK 3 million in annual revenue.

    • Tesco has declared an interim dividend of 4.80 pence per share for the 26-week period ended 23 August 2025. The dividend is scheduled for payment on 21 November 2025, in line with the company’s updated dividend policy.

    Continue Reading

  • Crystal Palace vs Man United LIVE: Latest updates from Selhurst Park

    Crystal Palace vs Man United LIVE: Latest updates from Selhurst Park

    Manchester United head to Crystal Palace on Sunday for a crucial Premier League clash, and you can follow it all live with ESPN right here.

    United appeared to have turned a corner after five league games unbeaten, but last…

    Continue Reading

  • NeurologyLive® Brain Games: November 30, 2025 | NeurologyLive

    NeurologyLive® Brain Games: November 30, 2025 | NeurologyLive

    Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields…

    Continue Reading

  • Black Friday PlayStation deals that are still live: PS5 consoles are $100 off, plus discounts on games, accessories and more – Engadget

    1. Black Friday PlayStation deals that are still live: PS5 consoles are $100 off, plus discounts on games, accessories and more  Engadget
    2. Every PS5 DualSense Controller Deal Still in Stock After Black Friday  IGN
    3. Sony Is Still Holding the PlayStation…

    Continue Reading

  • Chernobyl Fungus Appears to Have Evolved an Incredible Ability : ScienceAlert

    Chernobyl Fungus Appears to Have Evolved an Incredible Ability : ScienceAlert

    The Chernobyl exclusion zone may be off-limits to humans, but ever since the Unit Four reactor at the Chernobyl Nuclear Power Plant exploded nearly 40 years ago, other forms of life have not only moved in but survived, adapted, and appeared…

    Continue Reading

  • Illegal weight-loss drugs being sold in UK by firms with high Trustpilot scores | Health

    Illegal weight-loss drugs being sold in UK by firms with high Trustpilot scores | Health

    Companies selling illegal weight-loss drugs are amassing positive Trustpilot reviews as critics say regulatory gaps allow high-risk operators to appear credible.

    A Guardian investigation found that Retatrutide UK had a score of 4.4 on the global review site, despite purporting to offer a drug that is unlicensed and illegal to sell or buy. Its website sells a 20mg retatrutide pen for £132.

    It is among a number of operators promoting themselves on the review website to appear legitimate. Academics have said the findings are alarming, showing how easy it is for people to be drawn into unregulated markets.

    One reviewer of Retatrutide UK on Trustpilot wrote: “So far so good. My pen arrived quickly and … First few pounds off and still feeling well with it. Would recommend.” The company did not respond to a request for a comment.

    Retatrutide, which has not yet completed clinical trials, is an experimental injection developed by the US drugmaker Eli Lilly that targets three gut hormones: GLP-1, GIP and glucagon.

    Early studies suggest it could help patients lose up to a quarter of their body weight, leading to it being hailed online as the next Ozempic. Ozempic is not licensed in the UK as a weight-loss drug.

    Buying Retatrutide illegally, however, carries serious risks. Because the drug is still experimental, products sold online or through unofficial channels are unregulated and may not contain the correct ingredients or dosage and may not be sterilised to the correct standard.

    Contaminated or incorrectly dosed injectable hormones can cause infections, dangerous blood sugar crashes, pancreatitisand cardiovascular side effects. Using an unfinished clinical-trial drug outside legitimate medical settings is unsafe and potentially life-threatening.

    Alluvi Health Care, the company at the centre of a recent weight-loss drug raid by the Medicines and Healthcare products Regulatory Agency, was also reviewed on Trustpilot. The MHRA and police raided an illicit facility manufacturing and distributing unlicensed products labelled as being produced by Alluvi in October.

    Alluvi Health Care, the company at the centre of a recent weight-loss drug raid by the MHRA, was also reviewed on Trustpilot. Photograph: MHRA/PA

    The company nevertheless had a 3.5 Trustpilot rating, accompanied by an AI-generated summary stating: “Customers are generally satisfied with the company’s products, order processing and delivery service.” Alluvi Health Care did not respond to a request for a comment.

    Another seller, operating under the name Retatide claims to be “powered by retatrutide, a cutting-edge triple-action peptide formula”. It tells customers that “people are switching daily after stalling on Mounjaro or Tirzepatide”.

    Its Trustpilot page gives a 4.6 rating with a plethora of five-star reviews. When approached by the Guardian, the seller said it had “disengaged from Retatide.com and Retatrutide … several months ago”.

    A separate site, Retatrutide Pens, had a 4.7-star Trustpilot rating, but its webpage displayed an “immediate closure notice”. Trustpilot’s algorithm provided an upbeat overview, saying customers “overwhelmingly had a great experience”, praising the product’s discreet packaging.

    It comes as TikTok accounts offer Black Friday deals on retatrutide and similar drugs. One company posted: “Yep … it’s happening” alongside a banner advertising “20% off + free next day” delivery, using hashtags such as “ratatouille” – code for retatrutide – and “tirzepatide”. Another account advertised “reta 40mg” at 25% off.

    The trading and marketing of high-risk goods and services is not allowed, according to a TikTok spokesperson. They said it had banned the hashtags #retatrutide and #reta, and would continue to remove content that violates guidelines.

    Emily Rickard, of the University of Bath, who researches the political economy of the pharmaceutical industry, said: “In our research we consistently uncover advertising rule breaches across regulated online weight-loss services, exposing how weak the current safeguards are even surrounding officially approved products.

    “Against that backdrop, the prevalence of illegal sellers offering unlicensed drugs like retatrutide – and presenting themselves as legitimate via glowing Trustpilot reviews – is especially alarming and dangerous. It shows how within just a few clicks people can be drawn into unsafe, unregulated markets.”

    Piotr Ozieranski, a reader in sociology at Bath, said: “The regulators should move towards starting investigations into suspected unethical practices proactively and use administrative fines linked to company turnover or market share.

    “Currently, it feels that the worst that can happen is that a company gets a slap on the wrist, and the public is often left unprotected.”

    Chris Emmis, the co-founder of the verification firm KwikChex, said: “Rogue and criminal operators rely on social media and supposedly ‘trusted’ online reviews to persuade consumers to buy these products. Urgent action is needed.”

    Trustpilot has since taken action to block all businesses highlighted in the Guardian’s investigation. It said it was an “open review platform, meaning that anyone can create a profile for a business and submit a review”, but that it removes and blocks business thatdo not align with its ethical standards.

    A spokesperson said: “As with other misuse, such as review fabrication, bad actors are continuously evolving their tactics in an attempt to circumvent our detection. Alongside other high-risk industries, we continue to investigate companies selling drug-related products and evolve our processes to protect the integrity of the platform.”

    A spokesperson for the MHRA said: “Public safety is the number one priority for the MHRA, and its criminal enforcement unit works hard to prevent, detect and investigate illegal activity involving medicines and medical devices and takes robust enforcement action where necessary.”

    Continue Reading